SEC Form 4 · accession 0001209191-16-111280

FIVE PRIME THERAPEUTICS INC · FPRX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Senior Vice President and CFO

Period of report

Mar 29, 2016

Accepted (ET)

Mar 31, 2016 · 6:39 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001175505

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Mar 29, 2016	M	4,824	$4.56	A	85,751	D
Common Stock^F3	Mar 29, 2016	S	4,824	$40.00	D	80,927	D
Common Stock	Mar 30, 2016	M	9,052	$4.56	A	89,979	D
Common Stock^F4	Mar 30, 2016	S	9,052	$40.01	D	80,927	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F5	$4.56	Mar 29, 2016	M	4,824	D	—	Oct 20, 2019	Common Stock	4,824	9,403	D
Employee Stock Option (right to buy)^F5	$4.56	Mar 30, 2016	M	9,052	D	—	Oct 20, 2019	Common Stock	9,052	351	D

F1Includes 247 shares granted to the reporting person by Five Prime Therapeutics, Inc. (the "Company") pursuant to a company match under the Company's 401(k) plan.
F2The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on November 30, 2015.
F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.04, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 and 4 to this Form 4.
F4The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.05, inclusive.
F5This option is fully vested and immediately exercisable.